E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
The effect of oestrogen replacement therapy taken either orally or transdermally and observing any likely benefit of both these therapies on the risks Venous thromobembolic events and cardiovascular heart disease. |
|
E.1.1.1 | Medical condition in easily understood language |
Looking at oral vrs Patch HRT and their beneficial effects on Heart disease
|
|
E.1.1.2 | Therapeutic area | Body processes [G] - Physiological processes [G07] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 16.1 |
E.1.2 | Level | HLGT |
E.1.2 | Classification code | 10027309 |
E.1.2 | Term | Menopause and related conditions |
E.1.2 | System Organ Class | 10038604 - Reproductive system and breast disorders |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To assess the cardiovascular system differences regarding coagulation activation(oral versus trans-dermal HRT). |
|
E.2.2 | Secondary objectives of the trial |
To assess the cardiovascular system differences regarding insulin resistance, lipids/lipoproteins and fibrinolysis in each of the groups (oral versus trans-dermal HRT). |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
Healthy and postmenopausal woman who have had a normal ultrasound result during the study screening visit (or obtained during routine clinical care and within 6 weeks of the visit taking place).
aged 40 - 60 years at least 1 year post last menstrual period (per participant report) BMI 18 - 32 Verbal confirmation of a normal mammogram within 2 years of study commencement continue on any concomitant medications without any change during the study give informed consent
|
|
E.4 | Principal exclusion criteria |
• Estrogen or androgen therapy during preceding 3 months • use of hormone implants during the preceding 12 months • have received any medications which may interfere with the study (SSRI, anti-androgens, PDE5 inhibitors, DHEA, SERMS) • have a significant psychiatric disorder • have a history of breast cancer • have diabetes, thrombo-embolic disorders, cardiovascular disease, any condition affecting carbohydrate metabolism, uncontrolled hypertension and uncontrolled hyperlipidaemia
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
Thrombin generation will be the primary endpoint. Thrombin is a serine protease: enzymes that cleave peptide bonds in proteins that in humans is encoded by the F2 gene. Prothrombin (coagulation factor II) is proteolytically cleaved to form thrombin in the coagulation cascade, Thrombin in turn acts as a serine protease that converts soluble fibrinogen into insoluble strands of fibrin, as well as catalyzing many other coagulation-related reactions. Measurement of time to peak thrombin generation has been shown to be a useful marker for coagulation activation. |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
It will be measured at the start and at the end of the study, and analysed as a continuous variable. |
|
E.5.2 | Secondary end point(s) |
- Insulin resistance will be calculated from the fasting plasma glucose and insulin values using the established HOMA equation. - Total cholesterol, triglycerides and HDL cholesterol are measured directly and LDL cholesterol is ccalculated using the Friedwald formula. - Fibrin, D-dimers, activated protein C (APC) resistance, fibrinogen, factor VII. antithrombin and plasminogen activator inhibitor-1 (PAI-1) are measured directly as further markers of coagulation activation, fibrinolysis and susceptibility to venous thrombosis. |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
These will be measured at the start and at the end of the study, and analysed as continuous variables. |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | Yes |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | Yes |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | Yes |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 3 |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | |
E.8.9.1 | In the Member State concerned months | |
E.8.9.1 | In the Member State concerned days | |